Eton Pharmaceuticals, Inc. 8-K

What Happened
Eton Pharmaceuticals, Inc. (ETON) filed a Current Report on Form 8-K (Item 8.01) on May 1, 2026, announcing the commercial launch of HEMANGEOL® (propranolol) Oral Solution. The press release states HEMANGEOL is the only FDA‑approved treatment for infantile hemangioma, a time-sensitive pediatric rare disease. Eton also said it has integrated its Eton Cares patient support services for the product.

Key Details

• Announcement date: May 1, 2026 (press release attached as Exhibit 99.1 to the 8-K).
• Product: HEMANGEOL® (propranolol) Oral Solution — described as the only FDA‑approved treatment for infantile hemangioma.
• Patient support: Eton Cares programs in place, including $0 co‑pay for eligible commercially insured patients and expanded patient assistance programs.
• Filing item: Reported under Item 8.01 (Other Events) of the Form 8-K.

Why It Matters
The launch puts an FDA‑approved, focused therapy for a pediatric rare disease into commercial distribution, which could affect Eton’s product revenue mix and patient reach over time. The $0 co‑pay and expanded assistance programs are designed to reduce patient access barriers, potentially supporting uptake among eligible insured and financially needy patients. The 8‑K contains no financial results or guidance; investors should watch for future updates on sales, uptake metrics, and any market launch performance disclosures.